WuXi Biologics Retains Spot on Hang Seng Sustainability Indexes
WuXi Biologics has secured continued inclusion in the Hang Seng ESG 50 and Corporate Sustainability Benchmark indexes, marking another year of recognition for the firm's environmental, social, and governance standards. The Shanghai-based CRDMO received an A+ rating in the 2026 assessment conducted by the Hong Kong Quality Assurance Agency.
The annual evaluation, performed by the Hong Kong Quality Assurance Agency on behalf of Hang Seng Indexes Company, scrutinized approximately 600 Hong Kong-listed constituents and over 1,300 A-share companies. The assessment framework targets industry-specific material factors, positioning the resulting indexes as key benchmarks for corporate ESG performance.
Dr. Chris Chen, CEO and Chairman of the ESG Committee, characterized the inclusion as validation of the company's Green CRDMO strategy. He noted that integrating sustainability into core operations serves as a foundation for long-term growth and industry innovation. The company currently employs over 14,000 staff across its global sites in China, the United States, Ireland, Germany, and Singapore.
This latest recognition adds to a growing portfolio of international accolades for the firm, including an AAA rating from MSCI and a Platinum Medal from EcoVadis. As of mid-2026, the company continues to support 1,064 integrated client projects, utilizing digital infrastructure and lean management to drive operational efficiency across its biologics value chain.
Comments (0)
No comments yet. Be the first!